Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION (Tables)

v3.21.2
SEGMENT INFORMATION (Tables)
 9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information
The following table presents information by reportable operating segment for the three and nine months ended September 30, 2021 and 2020 (in thousands):
Consumer Products
Segment		 Specialty Pharmaceutical Segment Consolidated Totals
Three months ended September 30, 2021:
Product sales, net $ 5,107  $ —  $ 5,107 
Gross profit $ 2,358  $ —  $ 2,358 
Research and development expense 126  284  410 
Selling, general and administrative expense 4,918  10  4,928 
Operating loss $ (2,686) $ (294) $ (2,980)
Three months ended September 30, 2020:
Product sales, net $ 5,564  $ —  $ 5,564 
Gross profit $ 2,458  $ —  $ 2,458 
Research and development expense 119  293  412 
Selling, general and administrative expense 5,188  9  5,197 
Operating loss $ (2,849) $ (302) $ (3,151)

Consumer Products
Segment		 Specialty Pharmaceutical Segment Consolidated Totals
Nine months ended September 30, 2021:
Product sales, net $ 15,079  $ —  $ 15,079 
Gross profit 7,006  —  7,006 
Research and development expense 380  441  821 
Selling, general and administrative expense 15,732  56  15,788 
Operating loss $ (9,106) $ (497) $ (9,603)
Nine months ended September 30, 2020:
Product sales, net $ 19,230  $ —  $ 19,230 
Gross profit 8,788  —  $ 8,788 
Research and development expense 575  2,092  2,667 
Selling, general and administrative expense 19,178  71  $ 19,249 
Operating loss $ (10,965) $ (2,163) $ (13,128)